Tags

Type your tag names separated by a space and hit enter

Bartholin's gland carcinoma: a 15-year experience.
Gynecol Oncol. 2001 Aug; 82(2):247-51.GO

Abstract

OBJECTIVE

Our objective was to review our experience with carcinoma of Bartholin's gland relative to treatment and oncologic outcome.

METHODS

Patient names were collected from our vulvar cancer database for the period September 1985 to September 2000. The medical records were retrospectively reviewed, and data were abstracted relative to demographics, presenting symptoms, treatment, and oncologic outcome.

RESULTS

We treated 12 women with Bartholin's gland carcinoma, and 11 patients are reported. Seven women presented with a painless vulvar mass, and 8 of 11 had initially been treated for an infectious process before referral to our institution. Squamous histology was most common, and the right gland was more frequently involved. Ten patients were treated with primary surgery, followed by adjuvant radiation in 7 for inadequate resection margins or lymphatic metastases. One patient was treated with primary chemoradiation. Stage I, II, III, IVA, and IVB disease was present in 3, 1, 4, 2, and 1 patient, respectively. Recurrence was suffered by 54.5% during a mean follow-up time of 73.5 months (median, 60; range, 8-180 months). Overall survival is 58.3% to date.

CONCLUSIONS

Conventional therapy for Bartholin's gland carcinoma yielded a 67% 5-year survival. Seventy-one percent of women receiving adjuvant radiotherapy recurred despite this precaution. Work is needed to identify an effective systemic therapy and to better determine which patients may benefit from pelvic radiotherapy.

Authors+Show Affiliations

Division of Gynecologic Oncology, University of South Florida, Tampa, Florida 33606, USA. rcardosi@tampabay.rr.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

11531274

Citation

Cardosi, R J., et al. "Bartholin's Gland Carcinoma: a 15-year Experience." Gynecologic Oncology, vol. 82, no. 2, 2001, pp. 247-51.
Cardosi RJ, Speights A, Fiorica JV, et al. Bartholin's gland carcinoma: a 15-year experience. Gynecol Oncol. 2001;82(2):247-51.
Cardosi, R. J., Speights, A., Fiorica, J. V., Grendys, E. C., Hakam, A., & Hoffman, M. S. (2001). Bartholin's gland carcinoma: a 15-year experience. Gynecologic Oncology, 82(2), 247-51.
Cardosi RJ, et al. Bartholin's Gland Carcinoma: a 15-year Experience. Gynecol Oncol. 2001;82(2):247-51. PubMed PMID: 11531274.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bartholin's gland carcinoma: a 15-year experience. AU - Cardosi,R J, AU - Speights,A, AU - Fiorica,J V, AU - Grendys,E C,Jr AU - Hakam,A, AU - Hoffman,M S, PY - 2001/9/5/pubmed PY - 2001/9/14/medline PY - 2001/9/5/entrez SP - 247 EP - 51 JF - Gynecologic oncology JO - Gynecol Oncol VL - 82 IS - 2 N2 - OBJECTIVE: Our objective was to review our experience with carcinoma of Bartholin's gland relative to treatment and oncologic outcome. METHODS: Patient names were collected from our vulvar cancer database for the period September 1985 to September 2000. The medical records were retrospectively reviewed, and data were abstracted relative to demographics, presenting symptoms, treatment, and oncologic outcome. RESULTS: We treated 12 women with Bartholin's gland carcinoma, and 11 patients are reported. Seven women presented with a painless vulvar mass, and 8 of 11 had initially been treated for an infectious process before referral to our institution. Squamous histology was most common, and the right gland was more frequently involved. Ten patients were treated with primary surgery, followed by adjuvant radiation in 7 for inadequate resection margins or lymphatic metastases. One patient was treated with primary chemoradiation. Stage I, II, III, IVA, and IVB disease was present in 3, 1, 4, 2, and 1 patient, respectively. Recurrence was suffered by 54.5% during a mean follow-up time of 73.5 months (median, 60; range, 8-180 months). Overall survival is 58.3% to date. CONCLUSIONS: Conventional therapy for Bartholin's gland carcinoma yielded a 67% 5-year survival. Seventy-one percent of women receiving adjuvant radiotherapy recurred despite this precaution. Work is needed to identify an effective systemic therapy and to better determine which patients may benefit from pelvic radiotherapy. SN - 0090-8258 UR - https://www.unboundmedicine.com/medline/citation/11531274/Bartholin's_gland_carcinoma:_a_15_year_experience_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-8258(01)96304-8 DB - PRIME DP - Unbound Medicine ER -